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Abstract
Background: The Janus kinase-signal transducer and activator of transcription (JAK/STAT)
pathway is one of the most important targets for myeloproliferative disorder (MPD). Although
several efforts toward modeling the pathway using systems biology have been successful, the
pathway was not fully investigated in regard to understanding pathological context and to model
receptor kinetics and mutation effects.
Results: We have performed modeling and simulation studies of the JAK/STAT pathway, including
the kinetics of two associated receptors (the erythropoietin receptor and thrombopoietin
receptor) with the wild type and a recently reported mutation (JAK2V617F) of the JAK2 protein.
Conclusion: We found that the different kinetics of those two receptors might be important
factors that affect the sensitivity of JAK/STAT signaling to the mutation effect. In addition, our
simulation results support clinically observed pathological differences between the two subtypes of
MPD with respect to the JAK2V617F mutation.
Background
The Janus kinase-signal transducer and activator of tran-
scription (JAK/STAT) pathway has been frequently
reported to be responsible for oncogenic processes such as
uncontrollable proliferation, apoptosis resistance, sus-
tained angiogenesis, and immune evasion [1]. Recently,
several research groups have demonstrated the existence
of a point mutation in JAK2 in most patients with poly-
cythaemia vera (PV), and approximately half of patients
with essential thrombocythaemia (ET) and primary mye-
lofibrosis (PMF) which are subtypes of myeloproliferative
disorder (MPD) [2-4]. The mutation results in a substitu-
tion of valine for phenylalanine at codon 617 of JAK2
(JAK2V617F) and leads to cytokine hypersensitivity and
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way. As a consequence, the expression of JAK2V617F
causes the production of hematopoietic colonies that are
characteristic of MPD patients.
Although JAK2V617F is well known to be an important
marker for MPD, it has also been reported that the fre-
quencies of the JAK2V617F allele in PV, ET, and PMF
patients are significantly different. The frequency of the
JAK2V617F allele in each MPD subtype is shown in Table
1. Moreover, homozygous JAK2V617F mutant erythroid
colonies can be grown from >30% of patients with PV,
while it is rarely observed in patients with ET (Table 1) [5].
Hematopoietic colonies grown from ET patients mostly
have wild type JAK2 or heterozygous JAK2 proteins. These
findings imply that there are important genetic differences
between PV and ET in terms of JAK/STAT signaling. Eryth-
ropoietin (Epo) and thrombopoietin (Tpo) induce JAK/
STAT signaling through the corresponding receptors, the
erythropoietin receptor (EpoR) and thrombopoietin
receptor (TpoR), and regulate the production of red blood
cells and platelets, respectively. Thus, it has been sug-
gested that JAK/STAT signaling through EpoR and TpoR
are related to PV and ET, respectively [4].
Furthermore, a dosage effect of JAK2V617F on JAK/STAT
signaling has been reported. Constitutive activation of
JAK/STAT signaling observed in cells transfected with only
the JAK2V617F gene were diminished when cells were
transfected with both the wild type and JAK2V617F gene
[2].
Although several efforts have been made for modeling the
JAK/STAT pathway [6-10], to the best of our knowledge,
there has been no comparative analysis performed for
JAK/STAT signaling through EpoR and TpoR that is related
to specific disease phenotypes. In this work, we aimed to
understand the role of the JAK2V617F mutation in the for-
mation of the disease phenotypes, PV and ET, through sys-
tems analysis. The main question of this work is how the
two cytokine ligands, Epo and Tpo, and the correspond-
ing receptors are related to PV and ET in regard to the acti-
vation of the JAK/STAT pathway. To study the different
dynamic characteristics, we considered not only the kinet-
ics of the receptors but also the relationship of the recep-
tors with JAK2. In addition, the behavior of the suppressor
of cytokine signaling (SOCS) protein, a negative regulator
of JAK/STAT signaling, was investigated.
Through this systems approach, we found that the
JAK2V617F mutation led to the over-activation of JAK/
STAT signaling and the effect of the mutation was differ-
ent between PV and ET based on the different receptor
kinetics, supporting the different mutation patterns clini-
cally observed in the patients.
Results and Discussion
Comparison of wild type JAK/STAT signaling through EpoR 
and TpoR
In the absence of continuous exposure of cytokine lig-
ands, both EpoR and TpoR did not transduce a signal
through the JAK/STAT pathway in wild type models, and
accordingly, the concentration of nuclear phosphorylated
STAT dimers (STAT*Dn) did not change (Figure 1). The
binding of cytokine to the receptors led to signal transduc-
tion and the concentration of STAT*Dn reached a peak
within 1 hour and reverted to its initial concentration,
suggesting that the negative regulators control the path-
way, regardless of receptor dynamics. Compared with
EpoR with a high disappearance rate (kd = 0.0452), TpoR
with a relatively low disappearance rate (kd = 0.0152)
showed a stronger effect on the level of peak concentra-
tion of STAT*Dn. The peak concentration of STAT*Dn
was increased by the signal transduction through TpoR
approximately 2~3 times as compared to STAT*Dn that
was increased by signal transduction through EpoR.
Comparison of JAK/STAT signaling with wild type JAK2 and 
JAK2V617F mutant proteins
As represented in Figure 2, with 8 hour continuous expo-
sure to Epo, the JAK2V617F mutant model shows a higher
level of STAT*Dn than the wild type model. The peak con-
centration of STAT*Dn in the mutant model increased
approximately 80 nM more than that in the wild type
model, and the concentration of STAT*Dn in the mutant
model decreased slowly as compared to that of the wild
type model (Figure 2A). The concentration of STAT*Dn
reverted to its initial concentration within 2 hours in the
wild type model while it reverted after more than 4 hours
in the mutant model. This observation indicates that the
negative regulator SOCS could not control JAK/STAT sig-
naling with the JAK2V617F mutant as effectively as with
the wild type model [11]. As similar to continuous Epo
exposure, of particular importance, the JAK2V617F
mutant model shows a high peak concentration even in
the absence of Epo (Figure 2B). This result is consent with
the known pathological condition observed in patients
Table 1: Frequency and mutational state of the JAK2V617F allele 
in MPD patients.
Mutational stateb
Disease Frequencya WT Hetero Homo
PV 81–99% - 68% 32%
ET 41–72% 40% 58% 2%
PMF 39–57% - - -
aAdapted from Levine et al. [4].bAdapted from Vannucchi et al. [5].Page 2 of 10
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The simulated concentration of nuclear phosphorylated STAT dimers with or without over 8 hour continuous 
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concentrations of  nuclear phosphorylated STAT dimers with and without continuous Epo exposure are shown in (A) and (B), 
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out ligand exposure [2].
The JAK2V617F mutant JAK/STAT signaling through TpoR
also showed an increased level of the concentration of
STAT*Dn in both cases with and without continuous
exposure to Tpo (Figure 3). However, the increased level
of STAT*Dn induced by the mutant model in JAK/STAT
signaling through TpoR was higher than that in the sign-
aling through EpoR. Whereas the concentration of
STAT*Dn in the wild type model decreased completely to
its initial concentration within 2 hours, the concentration
in the TpoR JAK2V617F mutant model was kept high for
more than 4 hours (Figure 3A). The TpoR JAK2V617F
mutant model was shown to increase the concentration of
STAT*Dn greatly (Figure 3B). The increased level and
duration of high concentration of STAT*Dn became larger
in the TpoR JAK2V617F mutant model than in the EpoR
JAK2V617F mutant model, indicating that the difference
in the receptor kinetics between the EpoR and TpoR
model can affect the response of the JAK2V617F mutation
on the pathway.
Comparison of JAK/STAT signaling with JAK2V617F 
through EpoR and TpoR
Figure 4 shows a comparison of the effects of the
JAK2V617F mutation on JAK/STAT signaling through
EpoR and TpoR. The peak concentration of STAT*Dn
induced by signaling through TpoR was much higher than
that through EpoR (Figure 4A). Moreover, the duration of
the high concentration of STAT*Dn was longer in signal-
ing through TpoR than that through EpoR. This observa-
tion was also found in the case without continuous ligand
exposure. In the absence of ligand, signaling through
TpoR produced approximately 130 nM of STAT*Dn more
than signaling through EpoR (Figure 4B).
Figure 5 illustrates the peak intensity and the duration of
JAK/STAT signaling through EpoR and TpoR in models
including wild type JAK2 or mutant JAK2 proteins
(JAK2V617F) under ligand exposure or no ligand expo-
sure. With ligand exposure, JAK/STAT signaling with the
JAK2V617F mutation through EpoR and TpoR increased
similarly, 3.1 and 2.8 times as strong in intensity, and 3.5
and 4.0 times as long in duration as with wild type JAK2.
However, without ligand exposure, which is an important
condition in terms of MPD pathology, there is virtually no
JAK/STAT signaling in the model with wild type JAK2, but
JAK/STAT signaling with the JAK2V617F mutant protein
showed a signifiacant increase in both intensity and dura-
tion. Interestingly, the amount of signaling increase
through TpoR is much larger than that through EpoR (198
versus 68 in intensity and 25 versus 17 in duration).
These findings suggesting that JAK/STAT signaling
through TpoR is more sensitive to the mutation effect
than through EpoR support that a lower frequency of the
JAK2V617F mutation is observed in ET patients than in PV
patients. JAK/STAT signaling through EpoR is considered
as mainly related with the production of red blood cells,
whose excessive increase is an important clinical charac-
teristic of PV patients, and signaling through TpoR is
related with the production of platelets whose excessive
production is a manifestation of ET. In addition, the find-
ings also support the rare homozygosity of JAK2V617F in
ET patients while a significant population of PV patients
carry homozygous JAK2V617F alleles.
Conclusion
This study has shown that a systems approach can be use-
ful for a comparative analysis of receptor kinetics of a sig-
nal transduction pathway in the context of the
pathological domain for understanding MPD, especially
JAK/STAT signaling through EpoR and TpoR. The simu-
lated results indicate that the difference of receptor kinet-
ics between Epo-induced and Tpo-induced JAK/STAT
pathway might affect the sensitivity of the pathway to
JAK2V617F, a gain-of-function mutation. Particularly, in
the absence of ligands (this condition might be critical in
chronic diseases as well as for MPD), JAK/STAT signaling
through TpoR with a higher cell surface expression and a
lower disappearance rate was more sensitive to the muta-
tion effect than through EpoR. Accordingly, the peak and
steady state concentration level of STAT*Dn, regarded as
an indicator of the amount of JAK/STAT signaling, was set
to an abnormally high level by the mutant model of JAK/
STAT signaling through TpoR. These observations can be
in accord with the clinical observation of the rarer
homozygosity of JAK2V617F in ET patients than in PV
patients. The effect of the mutation in PV is relatively weak
and the high rate of homozygosity or dosage of mutant
JAK2 proteins might be required to induce the PV pheno-
type [12,13].
In future work, to investigate the pathway with regard to
the pathogenesis of PV and ET, the model needs to be
extended further to include some proteins related with
disease phenotypes. Since PV patients can be character-
ized by an abnormal increase in the number of three types
of blood cells – erythrocytes, granulocytes, and platelets
[14] – the model for PV should involve hematopoietic
transcription factors such as GATA-1, GATA-2 [15,16], C/
EBPε and Fli-1 [17,18] that correspond to each lineage. In
addition, some previous studies have shown that the
cytokine receptors are also needed for JAK2V617F-medi-
ated transformation [19,20]. Therefore, it might be
informative to include JAK as a chaperone for the receptor
kinetics into the model.Page 5 of 10
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JAK/STAT signaling through TpoR including wild type and mutant JAK2 (JAK2V617F) proteins. The simulated 
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Effects of the JAK2V617F mutation on JAK/STAT signaling through EpoR and TpoR. The simulated concentrations 
of nuclear phosphorylated STAT dimers are presented in the solid curve (signaling through TpoR) and in the dashed curve (sig-
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The increased peak concentration (A) and the signal duration (B) of nuclear phosphorylated STAT dimers in 
the model with JAK2V617F proteins. The gray and black bars represent the wild type and JAK2V617F mutant model, and 
the numbers on the black bars denote the ratio of the concentration of [STAT*Dn] in the model with JAK2V617F to the 
model with the wild type JAK2 protein. We assumed [STAT*Dn] was 1 nM for the model with wild type JAK2 without ligands 
and the continuance duration was 0.1 hour to calculate fold changes in the model with the mutant JAK2V617F.Page 8 of 10
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JAK/STAT pathway model
We adopted the JAK/STAT pathway model by Yamada et
al. [7]. The schematic diagram (Figure 6) represents the
cytokine ligand (Epo or Tpo) induced JAK/STAT pathway.
The binding of ligand to the Receptor-JAK complex (RJ)
results in the dimerization of LRJ. The dimerized LRJ
(LRJ2) is phosphorylated by JAK and the phosphorylated
LRJ dimer (LRJ2*) phosphorylates STAT in the cytoplasm
(STATc). The phosphorylated STAT (STAT*c) dimerizes
(STAT*Dc) and translocates to the nucleus (STAT*Dn),
which functions as a transcription factor for various genes.
One of the genes induced by STAT*Dn is SOCS that inhib-
its the kinase activity of LRJ2*. STAT*Dn also induces
other proteins related to the cell proliferation of erythroid,
myeloid, and megakaryocytic lineage. The level of nuclear
phosphorylated STAT dimers (STAT*Dn) was considered
as the output of the pathway. We performed simulations
using the Systems Biology Toolbox [21] with Matlab (The
Mathworks, Natick, MA USA).
Receptor kinetics
To understand the dynamic differences of the Epo and
Tpo induced JAK/STAT pathway, we included receptor
kinetics. Several studies have demonstrated that in the
absence of JAK, a much larger fraction of the thrombopoi-
etin receptor (TpoR) (~5 times) than the erythropoietin
receptor (EpoR) is on the cell surface [22]. The studies
have also shown that TpoR is rapidly internalized from
the cell surface [23], and that Epo induces the rapid inter-
nalization and degradation of Epo while Tpo induces
long-lasting signaling in target cells [24]. These observa-
tions may indicate that TpoR has a lower degradation rate
than EpoR, which leads to the rapid recycling of TpoR
although EpoR and TpoR have a similar rate of internali-
zation. From previously reported experimental results
[22,23], we estimated the disappearance rate (kd) of EpoR
and TpoR, which comprises the internalization and degra-
dation rate for the sake of simplicity. It was estimated that
EpoR disappears approximately three times faster than
TpoR. The estimated relative surface expression levels and
disappearance rates are summarized in Table 2.
JAK2V617F mutant model
JAK2V617F mutant kinases bind to cytokine receptors and
are phosphorylated in the absence of ligands, leading to
the ligand-independent activation of downstream signal-
ing pathways [4]. We assumed that the phosphorylation
rate of cytoplasmic STAT depended on the concentration
of the receptor-JAK complex (RJ) as well as active ligand
binding receptors, as JAK2V617F is a gain-of-function
mutation independent of ligand binding or negative reg-
ulation. The chemical reaction by which JAK2V617F was
added to the wild type model is as follows:
d/dt(STAT*c) = WT reactions + kJAK2V617F × RJ
Table 2: Receptor kinetics constants.
EpoR TpoR
With Epo Without Epo With Tpo Without Tpo
Relative surface expression [24] 12 12 60 60
Disappearance rate of receptor 0.0452 0.0038 0.0152 0.0013
The JAK/STAT pathwayFigure 6
The JAK/STAT pathway. Each node indicates the com-
ponent involving the transduction signaling or negative regu-
lation of the pathway (R: receptor, JAK: JAK2, RJ: receptor-
JAK2 complex, Ligand: Epo or Tpo, LRJ: ligand bound RJ, Pc: 
cytoplasmic phosphatase, Pn: nuclear phosphatase, SOCS: 
negative regulator). * and D denote a phosphorylation and a 
dimerization, respectively. According to the location in a 
cell, each molecule is tagged by c (cytoplasm) or n (nucleus). 
The system output was calculated by the level of nuclear 
phosphorylated STAT dimers (STAT*Dn).Page 9 of 10
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